Prophylactic Early PN in HPT/BMT
Study Details
Study Description
Brief Summary
Supplemental prophylactic early parenteral nutrition will be commenced 1 day prior to conditioning chemoradiotherapy in patients who are not already malnourished. Supplemental parenteral nutrition continues throughout conditioning chemoradiotherapy and stem cell transplant.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
A standard parenteral nutrition solution will be used. The parenteral nutrition solution will be given once daily, and infused intravenously. The standard parenteral nutrition solution will contain approximately 40 grams of amino acids/L, 40 g lipids/L and 100g dextrose/L). Nutritional targets will be measured using indirect Calorimetry where available, or calculated via the Harris Benedict or Schofield equations. The dose of parenteral nutrition administered will be determined by the treating dietitian, treating physician or treating research team. The parenteral nutrition dose given will be individualised considering the patients clinical condition and body weight. The dose of supplemental parenteral nutrition will be dependent on the total calories also received from oral and/or enteral nutrition intake.
Supplemental parenteral nutrition will be discontinued when a patient is well enough to be discharged from hospital or when the patients attending clinician determines a central line is no longer needed for standard care. There is no maximum duration of supplemental parenteral nutrition..
Adherence to the study intervention will be monitored via medical chart reviews during site monitoring visits, and data queries on individual patient case report form documentation.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Standard Care The control group in this study is pragmatic standard nutrition care. Currently after a bone marrow transplant in Australia, patients are normally fed orally for as long as possible. If oral intake fails to provide sufficient calories for a period of two to three days, enteral or parenteral nutrition may be provided. |
Other: Pragmatic standard care.
Nutrition support will be provided as per usual care.
|
| Active Comparator: Early supplemental parenteral nutrition Supplemental prophylactic early parenteral nutrition will be commenced 1 day prior to conditioning chemoradiotherapy in patients who are not already malnourished. Supplemental parenteral nutrition continues throughout conditioning chemoradiotherapy and stem cell transplant. The dose of supplemental parenteral nutrition will be dependent on the total calories also received from oral and/or enteral nutrition intake. |
Dietary Supplement: Parenteral nutrition.
Nutrition support will be provides as per usual, but oral and enteral intake will be topped up with a standard parenteral nutrition solution. The standard parenteral nutrition solution will contain approximately 40 grams of amino acids/L, 40 g lipids/L and 100g dextrose/L).
Other: Pragmatic standard care.
Nutrition support will be provided as per usual care.
|
Outcome Measures
Primary Outcome Measures
- Disease free survival time [Recruitment will run for 3 years, with a median follow-up time of 2 years.]
Defined as time to relapse or death whichever occurs first
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients who are about to commence conditioning chemoradiotherapy for allogeneic haematopoietic progenitor/stem cell transplantation, who have a haematological malignancy, who are not meeting 80% of their Caloric needs via oral or enteral intakes, and who are not malnourished.
Exclusion Criteria:
-
Patients who are already receiving parenteral nutrition at time of screening.
-
Patients with a documented licensing contraindication to parenteral nutrition.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Royal North Shore Hospital | Sydney | New South Wales | Australia | |
| 2 | Royal Adelaide Hospital | Adelaide | South Australia | Australia | |
| 3 | Christchurch Hospital, CDHB | Christchurch | New Zealand |
Sponsors and Collaborators
- University of Sydney
- Australasian Bone Marrow Transplant Recipient Registry
- University of Roma La Sapienza
- Northern Clinical School Intensive Care Research Unit, University of Sydney
Investigators
- Principal Investigator: Gordon S Doig, PhD, Northern Clinical School Intensive Care Research Unit, University of Sydney
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NHMRC APP1108301
- ACTRN12615001329550
- U1111-1194-5952